Cargando…
Pembrolizumab in cervical cancer: latest evidence and clinical usefulness
Cervical cancer is the fourth most common cause of cancer-related deaths in women worldwide. With the development of detection of precancerous lesions and preventive human papillomavirus (HPV) vaccination program, a survival improvement has been observed in these patients in developed countries, alt...
Autores principales: | Borcoman, Edith, Le Tourneau, Christophe |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
SAGE Publications
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5455883/ https://www.ncbi.nlm.nih.gov/pubmed/28607581 http://dx.doi.org/10.1177/1758834017708742 |
Ejemplares similares
-
Keynote-158 study, FDA granted accelerated approval of pembrolizumab for the treatment of patients with advanced PD-L1-positive cervical cancer
por: Borcoman, Edith, et al.
Publicado: (2020) -
Hyperprogression under Immunotherapy
por: Frelaut, Maxime, et al.
Publicado: (2019) -
Paradigm Change in First-Line Treatment of Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma
por: Borcoman, Edith, et al.
Publicado: (2021) -
HDAC Inhibition to Prime Immune Checkpoint Inhibitors
por: Borcoman, Edith, et al.
Publicado: (2021) -
Clinical Development of Molecular Targeted Therapy in Head and Neck Squamous Cell Carcinoma
por: Gougis, Paul, et al.
Publicado: (2019)